Skip to content
Screener

Veracyte VCYT Testing revenue — Allocation of facilities and IT expenses

Similar metrics at other companies

Euronet Worldwide logo
EEFTIT — Revenue
$53.65M+9.0%
Orthofix Medical Inc. logo
OFIXIT — Revenue
$6M+6.3%
Allogene Therapeutics logo
ALLOReportable Segment — Facilities & IT-related spend
$6.42M-12.3%
Core Scientific, Inc. logo
CORZColocation revenue — Depreciation expense
$4.62M+4,343%
Rein Therapeutics Inc. logo
RNTXFacilities And Other Expenses — General And Administrative Expense
$508K+8.1%
Rein Therapeutics Inc. logo
RNTXFacilities And Other Expenses — Research And Development Expense
$25K+56.3%

Other financials

Income statement

See full
Revenue$139.1M+21.5%
Gross profit$101.2M+27.2%
Operating income$22.6M+680%
Net income$28.7M+307%
EPS (diluted)$0.35+289%

Balance sheet

See full
Cash & equivalents$264.8M+41.0%
Total debt$39.3M-22.1%
Total equity$1.3B+12.5%
Total assets$1.4B+9.2%

Cash flow

See full
Operating cash flow$35.2M+557%
CapEx$3.0M+62.8%
Free cash flow$32.3M+810%

Valuation

See full
Market cap$3.71B+97.6%
Enterprise value$3.48B+104%
P/E42.2×-29.1×
P/S6.9×+2.9×

Profitability

See full
Gross margin70.9%+2.9pp
Operating margin14.3%+9.2pp
Net margin16.2%+9.1pp
FCF margin28.7%+11.7pp

Returns & leverage

See full
Return on equity6.9%+4.1pp
Debt / equity0.0×
Current ratio9.3×+4.2×

Where this comes from

Reported directly by Veracyte in its filing.

Tagged under the XBRL concept vcyt:CostOfRevenueAllocationOfFacilitiesAndInformationTechnologyExpenses.

The source filing: Veracyte’s 10-Q, filed May 6, 2026.

Filed
May 6, 2026, 8:07 AM EDT
Fiscal quarter
Q1 FY2026
Calendar quarter
Q1 2026
Accession
0001384101-26-000031
Line itemThree Months Ended March 31, 20262025
Sample collection expense3,2882,825
Compensation expense9,8045,611
Other cost of testing revenue (1)4,9373,385
Allocation of facilities and IT expenses2,9633,372
Total cost of testing revenue33,30628,260
Cost of product revenue:
Product costs1,401109
License fees and royalties313324

Item 1. Condensed Consolidated Financial Statements (Unaudited)

FAQ

What is Veracyte's testing revenue — allocation of facilities and IT expenses?
Veracyte (VCYT) reported testing revenue — allocation of facilities and IT expenses of $2.96M in Q1 2026.
How has Veracyte's testing revenue — allocation of facilities and IT expenses changed year-over-year?
Veracyte's testing revenue — allocation of facilities and IT expenses decreased by 12.1% year-over-year, from $3.37M to $2.96M.
What is the long-term trend for Veracyte's testing revenue — allocation of facilities and IT expenses?
Over 3 years (2022 to 2025), Veracyte's testing revenue — allocation of facilities and IT expenses has grown at a 33.1% compound annual growth rate (CAGR), from $5.76M to $13.58M.
What does testing revenue — allocation of facilities and IT expenses mean?
This represents the portion of corporate facilities, infrastructure, and information technology costs allocated to the diagnostic testing segment. It reflects the indirect overhead burden required to support the physical and digital laboratory environment.

Ask your AI about Veracyte's testing revenue — allocation of facilities and it expenses.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude